‘A Massive Breakthrough’: Daily Pancreatic Cancer Pill Clears Tumours in One in 12 Patients

A once-daily pill combined with standard chemotherapy has produced the most striking results yet seen in pancreatic cancer, with tumours becoming undetectable on scans in roughly one in 12 patients…

Published 4 min read

‘A Massive Breakthrough’: Daily Pancreatic Cancer Pill Clears Tumours in One in 12 Patients

A once-daily pill combined with standard chemotherapy has produced the most striking results yet seen in pancreatic cancer, with tumours becoming undetectable on scans in roughly one in 12 patients and shrinking or disappearing in more than 60 per cent of those treated, according to clinical trial data presented Friday at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona.

The drug, daraxonrasib, was tested in 61 patients with treatment-naive metastatic pancreatic ductal adenocarcinoma (PDAC)—cancer that had already spread beyond the pancreas—in the Phase 1/2 RMC-GI-102 study. At a median follow-up of 18.3 months, the confirmed objective response rate was 60.7 per cent, including complete responses in 8.2 per cent of patients. The disease control rate—patients whose tumours stopped growing—was 90.2 per cent.

“In about one in 12 patients, it completely disappeared,” said Dr Wungki Park, a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center in New York who presented the findings. He described the results as “a massive, massive breakthrough”.

Survival and Durability

Median progression-free survival—the time before the cancer began growing again—was 12.8 months, and the median duration of response was 11.1 months. The twelve-month overall survival rate was 76.6 per cent.

For context, patients with metastatic pancreatic cancer receiving conventional chemotherapy typically survive eight to 11 months, with tumour shrinkage in about 23 to 42 per cent of patients and disease progression resuming after five to six months. In a separate Phase 3 trial, RASolute 302, daraxonrasib doubled median overall survival in previously treated patients compared with chemotherapy—13.2 months versus 6.7 months—with a twelve-month survival rate of 53.2 per cent versus 17.3 per cent.

“We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival,” Park said.

Drugging the ‘Undruggable’

Daraxonrasib, developed by US biotechnology company Revolution Medicines and marketed as Rasonque, targets the RAS family of proteins—mutations in which drive upwards of 90 per cent of pancreatic cancers. For more than three decades, scientists believed these mutations were impervious to treatment. The drug works through a “molecular glue” mechanism, binding to both the abundant cellular protein cyclophilin A and RAS, preventing RAS from interacting with its signalling partners. Unlike earlier KRAS-targeted drugs that address a single mutation, daraxonrasib is multi-selective, potentially helping far more patients.

The drug received US Food and Drug Administration approval in August 2026 for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy, or who are not candidates for multi-agent treatment—the first-ever RAS-targeted therapy approved for pancreatic cancer. The European Commission followed with approval in November 2026 for previously treated metastatic disease.

A Cancer That Kills Within a Year

The urgency of the findings is difficult to overstate. Pancreatic cancer has the lowest five-year survival rate of all common cancers—below 10 per cent in the UK—and one-year survival stands at just 23 per cent in England and Wales. An estimated 75 per cent of patients die within 12 months of diagnosis. The disease is notoriously silent, with symptoms—jaundice, itchy skin, darker urine, pale stools, unexplained weight loss, fatigue and high temperature—often appearing only after the cancer has spread. Actor Alan Rickman died of the disease in 2016, five months after diagnosis.

In Britain, there are around 11,500 diagnoses and 10,200 deaths each year, according to Cancer Research UK.

Hope Beyond the Pancreas

Because KRAS mutations also drive lung, colorectal, ovarian and endometrial cancers, daraxonrasib’s success could extend well beyond PDAC. The drug is already being tested in Phase 1 trials for non-small cell lung cancer, ovarian neoplasms and other solid tumours harbouring RAS mutations.

“I would hope that the early success that we are beginning to see in pancreatic cancer can also be rolled out to other cancers,” said Dr Sam Godfrey of Cancer Research UK, which called the results “the biggest leap forward in decades”.

The Caution That Must Follow

Despite the enthusiasm, researchers stressed that the trial was small, single-arm and not randomised, meaning the results cannot yet establish whether the combination definitively extends overall survival compared with chemotherapy alone. A larger international Phase 3 trial, RASolute 303, is now investigating daraxonrasib—alone and with chemotherapy—in treatment-naive metastatic PDAC. Side effects in the trial included rashes, diarrhoea and fatigue, with 5 per cent of patients discontinuing treatment because of daraxonrasib-related toxicity.

“We do not yet know whether these promising results will translate into longer overall survival,” said Professor Shivan Sivakumar of the University of Birmingham.

For now, the data offer something pancreatic cancer patients have rarely had: a reason to believe that the disease’s decades-long resistance to meaningful treatment may finally be cracking. As Dr Godfrey put it, “we are finally seeing progress in pancreatic cancer, which is so long overdue”.

Share this story

Get the AfroAsia Media newsletter

The day's top stories from Africa and Asia, straight to your inbox.

Comments

0 comments

Loading…